Subscribe to NRx Newsletter

NRX-101

NRx Press Release
Nov. 12, 2021
NRx Pharmaceutical’s Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright 7th Annual Israel Conference

Conference Begins on November 15, 2021 RADNOR, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) — NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer, Jonathan Javitt, will be presenting updates to the Company’s business at the H.C. Wainwright 7th Annual Israel Virtual Conference. Details of the presentation can […]

Read More
Aug. 24, 2021
NRx Pharmaceuticals Announces Closing of $30 Million Private Placement

RADNOR, Pa., Aug. 24, 2021 /PRNewswire/ — NRx Pharmaceuticals (Nasdaq: NRXP), today announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of common stock. The Company issued to the investors in the private placement unregistered preferred investment options (the “investment options”) to purchase up to an aggregate of 2,727,273 shares of […]

Read More
Aug. 10, 2021
NRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021

NRx Advancing Investigational Medicines for Critical COVID-19 and Other Respiratory Conditions, Vaccine to Prevent COVID-19 and Breakthrough Drug for Suicidal Depression and PTSD RADNOR, Pa., Aug. 10, 2021 /PRNewswire/ — NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced that the NRx Team, together with Prof Jonathan Javitt, Founder, Chairman and CEO of NRx, will […]

Read More